TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30252895
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 30 min/day for 8 weeks
Study: 27209465
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid
Study: 27209465
Drug: Pasireotide 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 900 μg sc bid
Study: 15130080
Drug: Oral Balance
Normalized name: Biotene Oral Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Balance gel (used three times a day for 90 days)
Study: 15130080
Drug: gel placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel placebo (used three times a day for 90 days)
Study: 9164361
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 micrograms once daily for 4 weeks
Study: 8431629
Drug: Hourly pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly pain assessments for 48 hours using VAS
Study: 2959626
Drug: Antitissue immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitissue immunoglobulins (Sérocytol Neuro‐Vasculaire) administered by intradermal injections
Study: 362293
Drug: Immuno-chemotherapy (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-chemotherapy (1 mg Corynebacterium parvum i.v. on days 1-4 + MeCCNU 200 mg/m2 on day 8, repeated every 7 weeks)
Study: 362293
Drug: Chemotherapy (MeCCNU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (MeCCNU, 200 mg/m2, given orally every 8 weeks)
Study: 362293
Drug: Immuno-chemotherapy (C.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-chemotherapy (C. parvum + MeCCNU)
Study: 362293
Drug: Chemotherapy (MeCCNU)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (MeCCNU)
Study: 28345792
Drug: Basal-only insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-only insulin (n=120)
Study: 22152769
Drug: Bufei Yishen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Yishen Granule combined with acupoint‐sticking therapy
Study: 9625090
Drug: 600-mL preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mL preload
Study: 9625090
Drug: 300-mL preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mL preload
Study: 9625090
Drug: 450-mL preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450-mL preload
Study: 21036173
Drug: PEG alfa-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG alfa-2a (PEG-2a; 180 μg/1.73 m(2) body surface area, subcutaneously each week) and ribavirin (15 mg/kg orally in 2 doses daily)
Study: 15252294
Drug: Acamprosate (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (0, 2, and 4 g, p.o.)
Study: 11333096
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL fibrin sealant at axillary dissection site
Study: 11333096
Drug: 16 mL
Normalized name: 16 ML Mvasi 25 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mL fibrin sealant at axillary dissection site and 8 mL at skin flap site
Study: 8136395
Drug: Scopolamine and
Normalized name: butylscopolamine and analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine and morphine
Study: 3027153
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, 4 mg from a metered-dose inhaler
Study: 3027153
Drug: Cromolyn sodium,
Normalized name: Cromolyn Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn sodium, 20 mg from a Spinhaler
Study: 24765899
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0 mg (control)
Study: 23539257
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (ethinylestradiol 0.035 mg + norethisterone 1 mg)
Study: 16931264
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL injection volume of peribulbar anesthesia
Study: 16931264
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL injection volume of peribulbar anesthesia
Study: 10973836
Drug: Eptifibatide infusion
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide infusion for up to 72 to 96 hours
Study: 29600482
Drug: Placebo (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.4 mL·kg‐1 of 0.9% saline)
Study: 26658804
Drug: Lactulose oral
Normalized name: lactulose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose oral solution and polyethylene glycol electrolyte powder
Study: 20499122
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and standard physical therapy (group III)
Study: 20499122
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound in addition to standard physical therapy (group II)
Study: 20499122
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy including hot pack and exercise program (group I)
Study: 17110604
Drug: GW501516 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW501516 10 mg
Study: 17110604
Drug: GW501516 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW501516 2.5 mg
Study: 10419240
Drug: Cornstarch (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornstarch (0.3 g/kg)
Study: 7593726
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg daily)
Study: 7205167
Drug: Cephalexin administered
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin administered twice a day
Study: 7205167
Drug: Cephalexin administered
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin administered four times a day
Study: 30094983
Drug: Herbal cake-partitioned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal cake-partitioned moxibustion combined with Rhinocort nasal spray (2 jets/day for each nostril, 64 µg/jet) for 8 weeks
Study: 30094983
Drug: Rhinocort nasal
Normalized name: Rhinocort Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinocort nasal spray (2 jets/day for each nostril, 64 µg/jet) for 8 weeks
Study: 27322311
Drug: Omegaven(®) 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omegaven(®) 10% 100 mL/day for five days postoperatively
Study: 17767511
Drug: ASA 1000
Normalized name: Canasa 1000mg Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 1000 mg
Study: 16582548
Drug: MORA bioresonance
Normalized name: OCTINOXATE 0.0664 g in 1 g / OXYBENZONE 0.0151 g in 1 g TOPICAL LIPSTICK [ESIKA HYDRACOLOR 2 IN 1 SPF 25 (MORA GLAM) - BROWN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MORA bioresonance therapy
Study: 57244
Drug: Thiacetazone 150
Normalized name: Thioacétazone
DrugBank: Amithiozone (DB12829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiacetazone 150 mg with Isoniazid 300 mg once daily
Study: 57244
Drug: Paraaminosalicyclic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraaminosalicyclic acid 12 gm with Isoniazid 300 mg daily in divided doses
Study: 27266883
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (physical therapy only)
Study: 19411388
Drug: naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 750 mg bid
Study: 20828790
Drug: naproxcinod 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxcinod 375 mg bid
Study: 18708688
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (CR: 0.25 g/kg lean-tissue mass for 7 days; 0.06 g/kg lean-tissue mass for 49 days; n=22, 12 males, 10 females)
Study: 11427833
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion with propofol/alfentanil (Group II)
Study: 11427833
Drug: Nurse-administered midazolam/meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered midazolam/meperidine (Group III)
Study: 9566014
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic injection (LA)
Study: 3142349
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (600 mg)
Study: 25279807
Drug: QAM dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAM dosing of extended-release hydromorphone
Study: 25279807
Drug: QPM dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: QPM dosing of extended-release hydromorphone
Study: 23102797
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 800 mcg
Study: 21903473
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (bolus and infusional fluorouracil plus leucovorin, followed by oxaliplatin and irinotecan)
Study: 21903473
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (FOLFOX6 followed by FOLFIRI)
Study: 16352689
Drug: rosiglitazone (RSG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (RSG; 8 mg/d; n = 13)
Study: 31283521
Drug: Aspirin desensitization
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin desensitization combined with long-term Aspirin therapy
Study: 29425912
Drug: Low-dose prophylaxis
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prophylaxis antibiotics
Study: 29425912
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for urinary tract infection treatment
Study: 27168265
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week (following 80 mg at week 0)
Study: 15229059
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg/day)
Study: 7512433
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg
Study: 25195590
Drug: Every 2
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 2 weeks cetuximab (500 mg/m²)
Study: 25195590
Drug: Weekly cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly cetuximab (250 mg/m²)
Study: 23281805
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m2, day 1) plus carboplatin (AUC 6 mg/mL/min, day 1) every 3 weeks (Arm A)
Study: 23281805
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2, days 1 and 8) plus carboplatin (AUC 5 mg/mL/min, day 1) every 3 weeks (Arm B)
Study: 21668751
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine infusion (2 µg/kg/min)
Study: 21668751
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine infusion
Study: 18267006
Drug: Interferon gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma (1 x 106 IU recombinant human IFN gamma intramuscularly, daily for one month and then three times per week up to 6 months)
Study: 17087052
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA)-rich fish oil-fortified drink (0.60 g EPA + 0.26 g docosahexaenoic acid/d) for 12 weeks
Study: 11892888
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of melatonin
Study: 31452471
Drug: PROPER intervention
Normalized name: Propel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROPER intervention - structured and biannually repeated multidisciplinary medication review
Study: 19335686
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone
Study: 16684385
Drug: Daily supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplements for 5 days a week
Study: 16684385
Drug: Weekly supplements
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplements
Study: 11958389
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human bFGF administered weekly by intravenous infusions of 2 microg/kg for 6 weeks (total dose 12 microg/kg)
Study: 9042989
Drug: Lactulose 20
Normalized name: lactulose 20000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose 20 g t.d.s. for 15 days
Study: 9042989
Drug: Lactose 20
Normalized name: lactose 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose 20 g t.d.s. as placebo
Study: 7706699
Drug: 20mg lisinopril
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg lisinopril
Study: 25555797
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (54 μg per spray, mean total dose 734 μg, duration of use 3.5 h)
Study: 23132474
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg intravenously 1 hour prior to subarachnoid block
Study: 23132474
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) 2 ml intravenously 1 hour prior to subarachnoid block
Study: 17697450
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone in the treatment of chronic low back pain (CLBP)
Study: 17697450
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone in the treatment of pain associated with chronic osteoarthritis (OA)
Study: 15138569
Drug: 13‐cRA at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐cRA at a dose of 0.5 mg/kg per day per os
Study: 9690954
Drug: Tucaresol 200
Normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucaresol 200 mg after overnight fast
Study: 9690954
Drug: Tucaresol 200
Normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucaresol 200 mg after ingestion of a standard breakfast
Study: 9690954
Drug: Tucaresol 200
Normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucaresol 200 mg in females
Study: 9690954
Drug: Tucaresol 200
Normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucaresol 200 mg in males
Study: 7659481
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis vaccine (DTP)
Study: 2568785
Drug: Iotrolan 240
Normalized name: IOTROLAN 240MG/ML INJ INTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iotrolan 240 mg I/ml
Study: 2568785
Drug: Iotrolan 300
Normalized name: Iotrolan
DrugBank: Iotrolan (DB09487)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iotrolan 300 mg I/ml
Study: 409803
Drug: Clonazepam added
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam added to treatment
Study: 31880966
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus bevacizumab 15 mg/kg
Study: 25084742
Drug: Miconazole mucoadhesive
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole mucoadhesive buccal tablet (MBT)
Study: 25084742
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral amphotericin B suspensions
Study: 23535839
Drug: Eight cycles
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight cycles of anthracycline-based chemotherapy
Study: 21707626
Drug: Regular monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular monthly continuing education class (Control)
Study: 16432076
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with melphalan 140 mg/m2 plus total-body irradiation 12 Gy
Study: 16432076
Drug: Standard-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose therapy (SDT) using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone
Study: 16432076
Drug: Standard-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose therapy (SDT)
Study: 16432076
Drug: Further standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further standard-dose therapy (SDT) after relapse
Study: 11513193
Drug: Recombinant interleukin-12
Normalized name: Recombinant interleukin-12
DrugBank: Edodekin alfa (DB15631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interleukin-12 (rhIL-12) at a dose of 300 ng/kg
Study: 8489988
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% plus epinephrine at 650 mg
Study: 8489988
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% plus epinephrine at 500 mg
Study: 29450877
Drug: Preoperative paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative paracetamol (IV infusion of paracetamol 15 mg kg‐1 1 h before surgery)
Study: 29450877
Drug: Postoperative paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative paracetamol (IV infusion of paracetamol 15 mg kg‐1 in recovery room)
Study: 29450877
Drug: Control (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (IV infusion of saline pre‐ and postoperatively)
Study: 24357575
Drug: Multidimensional Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Treatment Foster Care for Adolescents (MTFC‐A)
Study: 12572529
Drug: tolterodine L-tartrate
Normalized name: Tolterodine L-tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine L-tartrate (2 mg twice daily)
Study: 9459246
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus 2 mL sodium bicarbonate 8.4%
Study: 2225951
Drug: Glycopyrrolate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (2 mg every 2 hours for 6 hours)
Study: 2225951
Drug: Metaproterenol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (15 mg every 2 hours for 6 hours)
Study: 24686
Drug: Antacid suspensions
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid suspensions (liquid form)
Study: 24686
Drug: Antacid chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid chewing tablets
Study: 28266242
Drug: Sertraline (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (135 mg daily)
Study: 16476843
Drug: Amlodipine+/−perindopril-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine+/−perindopril-based therapy
Study: 16476843
Drug: Atenolol+/−thiazide-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol+/−thiazide-based therapy
Study: 12742836
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching combined with at least 1 hour per day of near visual activities
Study: 12742836
Drug: 6 hours
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hours of daily patching combined with at least 1 hour per day of near visual activities
Study: 8603558
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) treatment with end-to-end anastomosis
Study: 8603558
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) treatment with side-to-side or end-to-side anastomosis
Study: 1419473
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (1 mg perindoprilat in 30 ml) over 1 h
Study: 1419473
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (1 mg perindoprilat in 30 ml) over 3 h
Study: 1419473
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (1 mg perindoprilat in 30 ml) over 6 h
Study: 1419473
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (30 ml) over 3 h
Study: 3965336
Drug: Bicozamycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicozamycin (500 mg four times a day for 3 weeks)
Study: 20722847
Drug: Testosterone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (5 mg/d)
Study: 15970828
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin (10 mg/d)
Study: 15970828
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine (4 mg/d)
Study: 12452243
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 10 mg and lornoxicam 16 mg
Study: 12452243
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 10 mg, lornoxicam 16 mg with 0.5% ropivacaine local skin infiltration before skin incision and 1% ropivacaine instillation before peritoneal incision
Study: 12452243
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 10 mg, lornoxicam 16 mg with 1% ropivacaine instillation after peritoneal closure and 0.5% ropivacaine local skin infiltration before skin closure
Study: 11563411
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (5 days high dose 1,050 mg/m2/day followed by 14 days low dose 700 mg/m2/day)
Study: 11563411
Drug: Alternate regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate regimen (two courses of high dose therapy separated by one week)